Pod Insights Equity Podcast The musician-turned-biotech-founder waiting to fundraise About this episode When Grammy-nominated singer-songwriter Aloe Blacc got COVID despite being vaccinated and boosted, he tried to fund research for a better solution. What he quickly found out? You can't just write a check in biotech. Regulators require a commercialization plan, and philanthropy doesn't move science through clinical trials or get you a license on university IP. Now, he's bootstrapping a cancer drug platform targeting pancreatic cancer, a disease that kills 90% of its patients, and intentionally waiting to raise from his network until peer-reviewed papers can make his case.
On this episode of TechCrunch's Equity podcast, Rebecca Bellan sits down with Aloe Blacc to talk about what happens when a creator decides to build instead of just invest, how Aloe is watching AI reshape both the biotech and music industries in real time, and his thoughts on who actually wins.
Listen to the full episode to hear:
How he’s navigating a world where credibility is earned in data, not fame
How a University of Houston molecule discovery platform could cut years off drug development timelines
Why he thinks record labels, not artists or AI companies, will ultimately control the economics of AI-generated music
What Suno taught him about prototyping, and why his next album will still be recorded with live musicians
Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Transcript 0:00 Speaker 00 This episode of Equity is brought to you by Schneider Electric. Schneider Electric, your energy technology partner.
0:05 Speaker 01 Hello and welcome back to Equity Tech Crunch's flagship podcast about the business of startups. I'm Rebecca Bellan and this is the episode where we bring on industry experts to help us explore a trend in the tech world and dive deep. This is a bit of a different episode for us. We don't usually have musicians on Equity, but as AI starts to reshape creative industries and as more creators start acting like investors, those lines are getting blurry.
0:34 Speaker 01 So today, we're joined by Grammy nominated singer songwriter Aloe Black. This isn't just a conversation about music, though. For those who aren't aware, Aloe is a biotech founder. So we're going to talk about how he found his way into cancer research, the funding behind it, FDA pipelines, and then how AI is reshaping the economics of the music industry. Aloe, welcome to the show.
0:53 Speaker 02 Hi, thank you for having me.
0:55 Speaker 01 So for those who don't know, you are the, the voice, the singer songwriter behind I Need a Dollar, which has been stuck in my head all day. The Man, Wake Me Up, there's that amazing Avicii song that you wrote. So thrilling to meet you.
1:07 Speaker 02 Yeah, thank you. Yes, I love writing songs and creating music. It's been a passion of mine and luckily has become my career after a short stint in business consulting.
1:20 Speaker 01 You're known as a musician, but now you're also building a biotech company and thinking about AI. How do you define what you do today?
1:27 Speaker 02 Well, I just enjoy trying to make as much impact as possible. The music is one way that I do it, but with biotech, my goal was to use my influence and my income to make a market difference in how we approach creating new therapies for disease, immune dysregulation, and for oncology. I was lucky enough to find a scientist who is at the University of Houston, a biological chemist named Dr. Gomika Uragamasoria, who is brilliant and he has a platform where he can produce and discover.
2:05 Speaker 02 Molecules that have tremendous efficacy in binding to biomarkers, any kind of biomarker. A lot of the research and science that's happening these days is drugs trying to bind to proteins, because those are the, historically, the biomarkers that scientists have identified as implicated in disease. But there are multiple types of structures within our system, and his molecules bind to any of the structures. And because of that, we've increased the ability to have effect on disease, because it's not just the proteins.
2:48 Speaker 01 I want to get into the nitty gritty of some of this tech and what made you invest in this. So you've taken, maybe we can come back to the stuff about music, because we've already set ourselves on this path. But you've taken a pretty different path than most artists. You didn't just invest in startups. Like, we see a lot of people use their wealth to invest in things that they believe in, but you actually went and built it. So you talked to us a little bit about the problem. If we could take a step back, like, when did your interest pivot to starting a company? And what problem were you trying to solve at the beginning?
3:20 Speaker 02 Well, in the past, I had invested in startups and learned really quickly that you're investing in the leadership of the startup, companies that didn't necessarily have success, but they had great ideas. Unfortunately, the person with the great idea was not the person to run the company, but they thought they were. And I figured out that it's really important to invest in the right leader. Otherwise, you have to have a very specific hand in the growth and the development of the company. So when it came to biotech, I was really just trying to do philanthropy, but learned quickly that it's such a cash-intensive industry that it requires more than just the philanthropy.
4:05 Speaker 02 It requires a little bit of administration. And the scientist who I was sponsoring needed help with the administration. So then I stepped in as an operator. Luckily, we've recently hired a CEO. But the difference was, is the other things that I've invested in, they were just...
4:25 Speaker 02 Novel ideas that were cool for the marketplace in, you know, social media apps or VR technology. But this is bigger. This is more of a double bottom line. This has an implication in making people healthier, saving lives, and improving the way that we even look at drug discovery and development.
4:54 Speaker 01 So you, I mean, when we first initially met at Web Summit Qatar, you talked about how COVID was the thing that kind of set you on this path. Right? Despite being vaccinated and boosted, you wanted to fund research for a more preventative solution. So that's when you learned that you can't just do philanthropy in this world of biotech. It requires funds and return on investment to, you know, put back into the company. Your first vehicle was Major Inc., I believe?
5:23 Speaker 02 Yeah, first vehicle was Major Inc. I started the company in order to get the IP from the university, get a license so that we could do the research on the molecule. Things that the university was not able to accomplish because they didn't have the facilities or the resources. We had to do outside. And in order to do it outside, we had to establish a company to then license out the IP. But we've pivoted since then because my co-founder's expertise is in oncology. And like with COVID, many of the scientists who are working on solutions had other expertise in their repertoire, but worked on COVID because it's such a demanding disease at the moment
6:07 Speaker 02 with a pandemic happening. mRNA technology is, you know, an example. It was designed initially for cancer, but it was not approved for use in humans until COVID. And then the trials for cancer accelerated after COVID. And now it is available for use in cancer. It just goes to show, you know, nothing like a good pandemic to get great technology through the regulatory hurdles. I think that's unfortunate. I think that there should be a system. That really does appreciate the science that is happening and offer, you know, these brilliant scientists an opportunity to bring their technology to
6:52 Speaker 02 the, to the people to save lives.
6:54 Speaker 01 Yeah, I agree. I once heard a horrible stat and I, no one take me at my face value here, but it could not be true. But I heard that the makeup industry gets more funding for research than cancer, which again, don't know if that's true, but I think that it, it does go to show that like often things that have a potential upside financially end up getting more attention than things that are actually useful and necessary. Right?
7:20 Speaker 02 Yeah.
7:20 Speaker 01 So what's been harder about biotech than you expected?
7:23 Speaker 02 Well, the hardest part about biotech ultimately is competing against other really smart scientists and projects to get the funding and convincing the investors. Any slight change in markets can scare investors away from making a bet. And this particular industry is extremely difficult because not only does it come with the headwind of science not working at the bench, it comes with the headwind of regulators not approving on the administrative side. And then, once it is approved, it comes with the headwind
8:01 Speaker 02 of potentially not working in human beings at the clinical trial. And then after that comes with the headwind of, once it is approved, the competition from other really smart technologies that are right at your tail. So.
8:17 Speaker 01 Yeah. Do you have a B C safety net for this? Like, how is this funded and structured? I imagine that, you know, when you're thinking about risks and timelines, these things take 10 plus years, right?
8:25 Speaker 02 They do. It's like 10 years and hundreds of millions of dollars. I have a fantastic network. We have yet to approach our network because we just really feel like the science needs to be a slam dunk story. And so far it is, but we're waiting for some published papers, peer reviewed papers to help bolster that story. At the moment, it's bootstrapped and we're seeking non-dilutive funding from government entities. We're in the University of Houston and Texas has a great cancer research ecosystem.
8:58 Speaker 01 So you want to use your platform to help make impact, right? And specifically, right now with biotech. At this stage, this non-dilutive funding, like I imagine your, a lot of your network would be great when you're starting to get that kind of like VC backing, right? Is it still useful at this earlier stage of non-dilutive funding, given the fact that you're not a scientist, you come from outside the field? How does that balance? Like, does your name carry weight in those circles in the same way?
9:26 Speaker 02 No, it doesn't carry weight in the circles. And so that's why I feel like we need to wait for some of the papers. And the papers will help because I can bring them to the room and not have to try to validate anything with my knowledge or my experience, but with the experience of, you know, a reviewed research. The folks that I could go to right now, who probably would offer angel funding, I sort of feel like I'd wait until later because there are shallow pockets and there are deep pockets and I'd rather wait for the deeper pockets, especially because we're approaching a cancer that has a very, very high unmet need.
10:11 Speaker 02 Pancreatic cancer is, you know, kills 90% of its patients. There are no drugs on the market right now that are approved specifically for pancreatic cancer in the way that we're doing it.
10:24 Speaker 01 And is this with Major Inc. or is this Pepto ID? That's the other business that you co-founded?
10:29 Speaker 02 Major Inc. was the first company that we started to approach COVID. We pivoted to cancer and so we created Pepto ID to kind of have a separate approach. But Major Inc. is sort of like a holding company for Kept ID.
10:47 Speaker 01 Okay, so then how does this work in terms of where the money comes from? Like, are you investing your own money? And then you're getting the non-dilutive partnerships? Is that pretty much how this is being funded at the moment?
10:59 Speaker 02 So far, bootstrapping with my own money. And non-dilutive would come from government entities and potential private foundations if we are successful in applying.
11:13 Speaker 01 Has AI changed, for the scientists that you're working with? Has AI changed how they do research and how they do drug discovery?
11:22 Speaker 02 Well, I think AI will ultimately impact how we are doing research and how we will do drug discovery. At the moment, it has not impacted, mainly because the process that Dr. Udo Gamasori had developed was sort of like AI before AI. You know, in silico, the AI drug discovery companies are identifying multiple, millions, millions of possible molecular structures. The bottleneck for them is that they have to go to the bench, produce the molecule, and then in vitro, identify whether the molecule actually works.
12:04 Speaker 01 Can you define in silico and in vitro for our listeners?
12:06 Speaker 02 In silico would be in the computer, they are designing with AI millions of molecular structures for drugs. And then in vitro would be in a petri dish at the bench in a lab, first manufacturing that molecule, so doing the chemistry work to manufacture the molecule in the lab. And then, in a petri dish, applying that drug to said biomarker, the cell or the protein or whatever it is they're trying to attach the molecule to. To see if it actually binds in physical space, not in just in a computer simulation. And so those areas are potential no-go
12:51 Speaker 02 locations or failure locations, valleys. Dr. Udo Gamasori actually has created the system where he can produce, physically produce, hundreds of thousands of molecules. So the second part is done. The first and second part are done. Not only has he created the simulated molecule, but he's also produced the physical molecule. So those two are a success. Then he goes to the bench to identify which of the hundreds of thousands of molecules will bind to the biomarker that he's trying to attach to. And he has a simple, you know, color-coded system to use process of elimination. And the molecules out of 100,000
13:35 Speaker 02 that bind to the particular biomarkers that he's trying to attach to, he can identify. And so by then, he's had three for three successes. And then from there, it's further optimization of the molecule, further testing. He's got 10 patents and each patent has come from this process. Every time he looks for a molecule to bind to a specific biomarker, he's successful. And so it really does reduce the process of search and development years, like knocks five years off the process and millions of dollars off the process.
14:13 Speaker 00 What moves our world forward? Energy. History has been shaped by it, revolutions won with it and progress dependent on it. For 190 years, Schneider Electric has been a leading force in this story, creating the technologies that harness energy and transform the competitive landscape. And today, in the dawning era of energy and industrial intelligence, Schneider is helping customers build more efficient, resilient and sustainable operations across every sector, from data centers to homes, from buildings to industry. Schneider Electric, your energy technology partner. Discover more at se.com.
14:50 Speaker 01 Yeah, I can imagine that similar processes will be used to accelerate the FDA pipeline as well. I mean, one could only hope.
14:58 Speaker 02 I would hope. It does get, at that point, once we've identified the molecule, we've validated its efficacy in vitro, then we go to animals, we validate its efficacy in animals, then we go to further analysis, which is whatever the FDA says we have to do before we can go in human. And in human is where you determine whether or not what works in animals works in humans. So we can't really, we can't accelerate that part. It has to be done safely and properly.
15:29 Speaker 01 Yeah, I imagine there is a lot of risk with that. And I think it's really interesting that with the biotech world, because there's been decades of history of testing drugs and their efficacies, there's already a framework for releasing this kind of tech. It kind of slots in, the tech kind of slots into the existing pipeline and just maybe speeds it up, right? Versus a lot of other things, like when AI touches creative industries, that doesn't have a framework or a pipeline. And I think like a lot of the, or maybe you can tell me if I'm wrong here, but it doesn't feel like there's the same framework.
16:06 Speaker 02 No. I mean, with creative industries, there's no regulatory body that we're worried about. And
16:13 Speaker 01 I mean, there's like copyright, but that's, it's super vague. It's unclear what it means. It's unclear, you know, if you're allowed to, if it's fair use to use people's content to train AI. And then it's like, who owns a model?
16:27 Speaker 02 From what I understand, the Copyright Office has made a determination that AI-created art is not copyrightable yet. And so, you know, I think if you're savvy, you will, you can use AI to help you ideate, and then you can create on your own so that you have access to copyright without using
16:49 Speaker 02 The material produced by AI.
16:52 Speaker 01 Yeah, so, okay, so if I'm an indie artist today, does AI give me leverage? Or does it make me more replaceable? And is the stuff I produce mine?
16:59 Speaker 02 Yeah, I, I think if you're an indie artist today, it's yes and, it's both. You are replaceable, because AI can do a lot of things that anybody who's coming out today can do. If you are business savvy, that's really what it comes down to. It's how you tell your story as a business person and how you market, build an audience. AI cannot get out into the physical world and tell that story. But that begs the question, how important is the physical world at this point? Social media is working really well. The potential that, that AI could do all of the work, an agent could do all of the work and convince people that it's, it doesn't even have to convince people that it's human.
17:41 Speaker 02 I think people will just accept whatever art they enjoy and appreciate.
17:47 Speaker 01 You think so?
17:48 Speaker 02 I'm convinced only because the most popular movie last year, or within the last year, was K-Pop Demon Hunters, which is a cartoon. And the music, even though it was made by humans, in my opinion, could have been made by AI, because it doesn't sound any different from the stuff I've heard made by AI. And so, the idea that a non-human, so an animated avatar-ish character or characters, can sweep the attention of, of the world, suggests to me that, yes, AI could do it.
18:26 Speaker 01 Has your own relationship with music creation changed, knowing that AI can replicate style and sound?
18:33 Speaker 02 No, I'm, I'm a bit old, old school and, and set in my ways, I guess. So, I just continue to make music the way that I did in the past. It's my My meditation and as long as I'm having fun, I know other people will have fun. I feel lucky that I was able to, you know, have some success and build an audience. So I don't have to compete against not only all of the saturated market that exists now with everybody having access to release music at any time. But also I don't have to compete against AI because I'm an incumbent.
19:11 Speaker 01 Yeah, that's really lucky.
19:14 Speaker 02 And I have songs that I think will last the test of time. So I'll always be able to to have an audience.
19:21 Speaker 01 Would you license your voice to an AI company?
19:23 Speaker 02 I would license my voice to an AI company with the caveats of, you know, having some oversight on content messaging and with the right negotiated payment structure.
19:37 Speaker 01 Yeah, like so artists should be paid if their model, if their voices are used? Or do you think they should be paid if their voices are used to train a model?
19:43 Speaker 02 Yeah, I think anyone who has created anything that goes into a model should be compensated for their work being used to train the model. And so that's the big, I guess, controversy at the moment. Some of the big major recording labels were suing some of the AI music companies because their music has been training the models. It's like, you know, if you have an AI music production program, create a blues song in the style of 1940s blues.
20:28 Speaker 02 It's, it obviously has to train from copyrighted material.
20:35 Speaker 01 Right.
20:36 Speaker 02 Less likely that if you're asking an AI production tool to make a 2026 styled pop song, less likely that it would have to train against copyrighted material because so many artists have put their content up online for.
20:58 Speaker 02 For free and it's available to the public. So then that makes it available to AI in a way that with the fine print that's in the in the social media apps that, you know, say a 1940s blues song wasn't compromised.
21:15 Speaker 01 Yeah, I'm curious about like the economics of this as well. Like a few weeks before we're recording this, you know, Futurism had an article about this guy in North Carolina, I think. He pled guilty for creating hundreds of thousands of songs with AI. And then he used bots to fraudulently stream his AI-generated songs billions of times. And he made like $8 million off of this, right? Like it's obviously, I don't know that he'll be keeping all of that money, but it's, um, I'm curious, like who benefits the most in your opinion economically if AI-generated music becomes mainstream?
21:48 Speaker 02 Ultimately, the record labels will benefit the most because ultimately what will happen will be the record labels will probably be able to control the uploads of AI. And if it's an AI artist, they'd probably be able to stop their streams and/or sort of strong arm the owner of that AI to do a deal with them. Otherwise, they won't be able to stream their music, if that makes any sense. Because the major labels own a significant portion of the streaming, the streaming companies. It was the negotiation that had to happen in order for the streaming companies to use
22:31 Speaker 02 their IP, then the record labels wanted to own the part of the platform.
22:36 Speaker 01 The same old people, but just finding new ways to squeeze.
22:39 Speaker 02 It's like extortion, yeah.
22:40 Speaker 01 Yeah, pretty much it's extortion. Okay. So is there a world, though, where artists maybe become platforms, right? Like your voice could be something that people build on.
22:47 Speaker 02 Yeah, I think, you know, at some point, there will be an opportunity. Right now, you know, the lion's share of the streaming is going to Apple Music and Spotify. Technology is always transforming. The AI companies, the companies that help artists that have AI production could ultimately then become the streaming platforms. And all artists will be there because eventually all artists will be using AI as a tool, if not as the. Beginning and end loop of creating. So I think that's
23:21 Speaker 01 Have you tried making music with AI? It feels like you've missed something. Like, I am an amateur singer and guitar player. But Mando, I love jamming with other people, right? Like, it really, it just brings something together. And I haven't tried using these AI tools. But like, how do you feel about it? Like, don't you miss that collaborative element?
23:39 Speaker 02 Jamming in real time feels great. I do it all the time on stage. And I have been using some of the tools, the AI tools as well. And for me, it's just as fun because I have, over the past 25 years, my career, I've got tens of thousands of voice memos. And these voice memos sit in my hard drive doing nothing. But as I'm driving, or I'm flying from one place to the next, or I can put one of my voice memos into an AI program. It can analyze the idea that I had and create a tune. And I can hear my idea in a fully produced way that I can then share with my musicians. And then we can go to the stage and do it.
24:25 Speaker 01 What tools are you using, out of curiosity?
24:27 Speaker 02 Suno is the one that I use the most, just because it seems to have the best user interface and it's the quickest response. I spent, in the studio the other day, I was in the studio with my musicians. It was six musicians.
24:46 Speaker 02 We spent five days in the studio. So, you know, count six musician fees times five for the full day, studio costs for five days. And I basically did with them what I do with Suno. I sang them my voice memos. I told them what parts to play. So I gave them my verbal prompts. We recorded 12 songs. And those songs have yet to be mixed or mastered or edited. They're still sitting in the hard drive.
25:19 Speaker 01 Right.
25:20 Speaker 02 And the difference with Suno is, those 12 songs, in the same amount of time, I could have done 100 songs and had them complete.
25:30 Speaker 01 But doesn't that risk drowning out? You know, more is not always more, right?
25:33 Speaker 02 More is not always, more is not always better. It's only for me. I don't necessarily plan to release that 100 songs.
25:40 Speaker 01 Right.
25:40 Speaker 02 I just wanna, I wanna be able to hear what they sound like.
25:46 Speaker 02 And then decide which ones should go out. And the best thing, the best thing for artists is that these AI programs so far do not offer the highest fidelity audio. So ultimately, it will go back to my band.
26:03 Speaker 01 So ultimately, it's just a prototype.
26:05 Speaker 02 It's a prototype that will go back to my band and everybody will play with the highest fidelity.
26:10 Speaker 01 We're seeing that in enterprise software too, right? Like vibe coding is people are just like, yeah, it's still breaks. So this is a prototype and then we go and build it ourselves.
26:18 Speaker 02 Yeah.
26:18 Speaker 01 Which, you know, I'm sure that'll change eventually, but for now, at least we all still have jobs.
26:24 Speaker 02 Right.
26:24 Speaker 01 So one last thing I want to ask you before we wrap up. You're someone who's at the intersection of tech, music, biotech. How do you think about AI's role differently than a pure scientist or a pure technologist might?
26:35 Speaker 02 I don't know that I'm thinking any differently from how a pure scientist may think of it. I recognize that it is a powerful tool that we can use to amplify our work. But here's how it might be different. For me, you know, humanity is about purpose. You're finding your purpose and engaging that purpose. And you can't just leave all of your work to the tech. Because then you have, you have no purpose, or unless you're going to find another purpose. For me, the journey is so much more valuable than the destination.
27:16 Speaker 02 And AI really does cut that journey time down. And so, I don't know.
27:25 Speaker 01 Yeah.
27:26 Speaker 02 In the business world, you're, you're kind of at the mercy of the speed of your competitor. So that's where AI helps you make that advantage. But it really does, it really does reduce the fun of, of the journey of business.
27:41 Speaker 01 Yeah, yeah, couldn't agree more. That's a great place to end it on. Thank you so much for joining us. We're out of time. Where can our listeners connect with you online? Or on tour? I don't know. Are you on tour?
27:51 Speaker 02 Yeah, best place to connect with me online is at aloeblack.com.
27:56 Speaker 01 Great. Okay, well, thanks so much again for joining us on the show. To our listeners, you can find me, I'm on X, Blue Sky, LinkedIn, Substack. You can find Equity at EquityPod on Blue Sky and X. Talk to you next time.
28:12 Speaker 01 Equity is hosted by TechCrunch senior reporters and produced by Teresa Locan Solo with editing by Cal. Subscribe on YouTube or wherever you get your podcasts and find out what's next at techcrunch.com/events. Thanks so much for listening and we'll talk to you next time.
Previous Luma AI's Amit Jain on why most world model companies are getting it completely wrong Next Tokenmaxxing, OpenAI's shopping spree, and the AI Anxiety Gap Page updated October 26, 2026 · transcript and summary are machine-generated